Stock Buybacks (Quarterly) Chart

View Stock Buybacks (Quarterly) for VRTX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Stock Buybacks (Quarterly) Chart
Start Trial

Historical Stock Buybacks (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 421.80M
March 31, 2026 309.90M
December 31, 2025 74.40M
September 30, 2025 1.063B
June 30, 2025 342.70M
March 31, 2025 409.40M
December 31, 2024 383.60M
September 30, 2024 299.30M
June 30, 2024 265.30M
March 31, 2024 114.30M
December 31, 2023 103.10M
September 30, 2023 101.60M
June 30, 2023 -30.30M
March 31, 2023 118.60M
December 31, 2022 -51.60M
September 30, 2022 -36.60M
June 30, 2022 -64.40M
March 31, 2022 -33.70M
December 31, 2021 333.46M
September 30, 2021 618.48M
June 30, 2021 -37.94M
March 31, 2021 409.39M
December 31, 2020 101.01M
September 30, 2020 86.21M
June 30, 2020 -133.46M
Date Value
March 31, 2020 220.43M
December 31, 2019 -162.55M
September 30, 2019 -30.43M
June 30, 2019 5.538M
March 31, 2019 36.22M
December 31, 2018 99.47M
September 30, 2018 -8.912M
June 30, 2018 48.60M
March 31, 2018 -78.40M
December 31, 2017 -46.64M
September 30, 2017 -150.32M
June 30, 2017 -136.64M
March 31, 2017 -11.25M
December 31, 2016 -17.06M
September 30, 2016 -17.46M
June 30, 2016 -24.86M
March 31, 2016 -8.846M
December 31, 2015 -45.90M
September 30, 2015 -51.84M
June 30, 2015 -46.23M
March 31, 2015 -41.62M
December 31, 2014 -73.34M
September 30, 2014 -83.33M
June 30, 2014 -57.81M
March 31, 2014 -60.13M

Stock Buyback Definition

Stock buybacks are when companies buy back their own stock, removing it from the marketplace. Stock buybacks increase the value of the remaining shares because there is now less common stock outstanding and company earnings are split among fewer shares.

Read full definition.

Stock Buybacks (Quarterly) Range, Past 5 Years

View Stock Buybacks (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Stock Buybacks (Quarterly) Benchmarks

View Stock Buybacks (Quarterly) Benchmarks
Start Trial
Gilead Sciences, Inc. 346.00M
Alnylam Pharmaceuticals, Inc. -33.56M
Regeneron Pharmaceuticals, Inc. 1.120B
Sionna Therapeutics, Inc. -0.749M
Biogen, Inc. -6.00M